These figures havent been established in human trials, and long-term human safety data doesnt exist
(2) F M Ng, W J Jiang, R Gianello, S Pitt, and P Roupas (2000)
BPC-157 was placed in Category 2 ("may present significant safety risks") in 2023, removed from that category in April 2026, and is now set for a Pharmacy Compounding Advisory Committee review in late July 2026, while CJC-1295 and Ipamorelin were placed in Category 2 back in October 2023
Batch documentation (e.g., Test Results) is available on request
Total body-fat mass came down more than with placebo or the approved comparison medicine, which helped show that most of the weight change was fat rather than lean tissue
Some protocols utilize 2 mg doses administered 2-3 times per week as an alternative approach that reduces injection frequency while maintaining effectiveness